Ready-to-Use Stable Cell Lines
AMSBIO has expanded its portfolio of stable cell lines. The new cell lines express endogenous or recombinant proteins and are available in a ready-to-use format.
Using AMSBIO stable cell lines provides an optimised solution for the manufacture of therapeutic and diagnostic protein, and for applications in drug screening, pharmacological research and toxicological studies.
The extensive portfolio of ready-to-use stable cell lines available from AMSBIO includes: Receptors (RAR a, IGF1 Receptor, Motilin Receptor MLNR...) ; Ion channels (CFTR, Nav1.7, Kv1.5…) ; Cell signaling (Notch, JNK, NF-?B, ERK…) ; Phosphodiesterases (aequorin, CNGA2, PDE1B…) ; Stem cell related (LGR5, OCT4, LIN28) ; Fluorescent (GFP, RFP, CFP, YFP) ; TetR ; Luciferase ; CRE recombinase / reporter ; p53 and DNA repair gene knock-down cell lines (PARP1, MUTYH, MSH2, MLH1, XRCC6, BRCA1, NBS1…).
AMSBIO also has extensive experience in cell line development and has an excellent track record of developing demanding custom cell lines for academic, biotechnology and pharmaceutical organisations worldwide. Using a lentiviral system, AMSBIO scientists with many years of experience in cell line development will quickly establish an optimised cell line according to customer specification. All AMSBIO custom cell lines are designed specifically to meet client specification, as well as the company's own rigorous internal QC criteria, all within demanding timelines.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...